>too bad Novartis tried to show how safe their drug was at 30 time the dose and Merck only cared about 3 times the dose. Sometime too much information, is too much information<
If NVS’ own statements today are to be believed, the approvable letter is not due to the skin lesions seen in monkeys but rather to renal clearance.
p.s. Interesting color on the diabetes market—thanks for posting.
Market Data 
Markets 
AI
